A new study has revealed serious safety concerns about the drug Xeljanz. The drug is approved by the FDA, but that doesn’t mean it’s safe. It’s not uncommon for the FDA to order post-marketing studies to gather information about its safety, efficacy, and optimal use. The new study also comes at a time when the safety concerns surrounding Xeljanz are growing. In 2012, the FDA approved the drug, but warned of serious health problems. That led the company, Pfizer, to order an additional safety study.
Applied For Approval For Ulcerative
The FDA’s review of the Xeljanz Study Reveals Serious Safety Concerns serious safety concerns. The drug was found to increase the risk of serious heart problems and cancer in patients with non-malignant squamous cell carcinoma. This warning comes as a result of Pfizer’s recent Xeljanz study, which compared the drug to two other TNF-inhibitors.
In the U.S., the company has a limited number of indications for Xeljanz. Nevertheless, it’s still important to note that Xeljanz is not approved for all patients, including those with rheumatoid arthritis. However, the high-dosing regimen is indicated for people with ulcerative colitis. The drug’s market is expected to grow by more than 10% at constant currencies to $2.4 billion by 2020. Meanwhile, Pfizer’s competitors, such as AbbVie, have products that target TNF receptors, such as Humira, and AbbVie has a JAK inhibitor, Rinvoq. The drug was recently approved to treat RA, but AbbVie has also applied for approval for ulcerative
While Xeljanz is available over the counter, the FDA is currently considering tighter restrictions for this drug. The agency has also warned doctors and patients about the drug’s possible adverse effects. Its approval will depend on how much the company wants to make a profit from Xeljanz. While the FDA isn’t putting a ban on the drug, this latest warning shows serious concerns about the drug’s safety.